Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BVS Bioventus	$7.64 +7.9%	$6.80	$5.81 ▼ $14.38	$631.67M	0.83	399,140 shs	603,873 shs
CATX Perspective Therapeutics	$3.68 +3.4%	$3.79	$1.60 ▼ $16.55	$273.29M	1.17	940,145 shs	579,561 shs
CMD Cantel Medical	$80.37	$82.48	$39.40 ▼ $89.76	$3.58B	1.55	626,604 shs	N/A
INFU InfuSystem	$9.57 -0.4%	$6.79	$4.61 ▼ $9.97	$196.29M	1.81	168,396 shs	167,703 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BVS Bioventus	+7.91%	+3.66%	+18.08%	+17.00%	-16.23%
CATX Perspective Therapeutics	+3.37%	+1.94%	-15.40%	+53.97%	-75.89%
CMD Cantel Medical	0.00%	0.00%	0.00%	0.00%	0.00%
INFU InfuSystem	-0.42%	-0.62%	+60.57%	+76.89%	+38.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BVS Bioventus	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	1.5641 of 5 stars	3.6	1.0	0.0	0.0	2.0	0.8	0.0
CMD Cantel Medical	1.5318 of 5 stars	0.0	0.0	1.7	4.1	0.6	2.5	0.6
INFU InfuSystem	3.6347 of 5 stars	2.0	5.0	0.0	0.0	3.3	4.2	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BVS Bioventus	2.75	Moderate Buy	$13.75	79.97% Upside
CATX Perspective Therapeutics	3.18	Buy	$12.56	241.18% Upside
CMD Cantel Medical	0.00	N/A	N/A	N/A
INFU InfuSystem	4.00	Strong Buy	$12.50	30.62% Upside

Current Analyst Ratings Breakdown

Latest CMD, BVS, CATX, and INFU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/21/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	BVS Bioventus	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BVS Bioventus	$564.14M	1.12	$0.61 per share	12.58	$2.80 per share	2.73
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
CMD Cantel Medical	$1.02B	3.52	$3.38 per share	23.78	$17.31 per share	4.64
INFU InfuSystem	$139.89M	1.40	$0.75 per share	12.79	$2.47 per share	3.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BVS Bioventus	-$156.23M	N/A	N/A	16.61	N/A	-7.11%	15.61%	4.01%	N/A
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	11/11/2025 (Estimated)
CMD Cantel Medical	$13.71M	$1.65	69.28	28.91	1.63	4.72%	12.13%	4.45%	N/A
INFU InfuSystem	$870K	$0.23	159.53	30.87	N/A	1.12%	2.78%	1.41%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BVS Bioventus	N/A	N/A	N/A	N/A	N/A
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
CMD Cantel Medical	$0.21	0.26%	N/A	12.73%	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BVS Bioventus	1.85	1.41	0.99
CATX Perspective Therapeutics	N/A	9.60	9.60
CMD Cantel Medical	1.16	2.72	2.00
INFU InfuSystem	0.50	1.98	1.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BVS Bioventus	62.94%
CATX Perspective Therapeutics	54.66%
CMD Cantel Medical	84.13%
INFU InfuSystem	71.13%

Insider Ownership

Company	Insider Ownership
BVS Bioventus	33.00%
CATX Perspective Therapeutics	3.72%
CMD Cantel Medical	10.70%
INFU InfuSystem	11.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BVS Bioventus	1,200	82.68 million	54.46 million	Not Optionable
CATX Perspective Therapeutics	70	74.26 million	65.21 million	Optionable
CMD Cantel Medical	3,669	44.51 million	N/A	Optionable
INFU InfuSystem	410	20.43 million	19.10 million	Optionable

CMD, BVS, CATX, and INFU Headlines

Recent News About These Companies

InfuSystem (NYSE:INFU) Director Sells $55,621.84 in Stock

August 23 at 9:39 AM | insidertrades.com

Grab These 4 Stocks With Solid Net Profit Margins to Boost Returns

August 21 at 9:50 AM | zacks.com

4 Medical Product Stocks to Watch From a Challenging Industry

August 14, 2025 | zacks.com

Are You Looking for a Top Momentum Pick? Why InfuSystems Holdings, Inc. (INFU) is a Great Choice

August 13, 2025 | zacks.com

Recent Price Trend in InfuSystems Holdings (INFU) is Your Friend, Here's Why

August 13, 2025 | zacks.com

Roth Capital Predicts Increased Earnings for InfuSystem

August 9, 2025 | marketbeat.com

B. Riley Issues Positive Estimate for InfuSystem Earnings

August 9, 2025 | marketbeat.com

Why InfuSystems Holdings (INFU) Might be Well Poised for a Surge

August 8, 2025 | zacks.com

Can InfuSystems Holdings (INFU) Climb 79.52% to Reach the Level Wall Street Analysts Expect?

August 8, 2025 | zacks.com

Are Investors Undervaluing InfuSystems Holdings (INFU) Right Now?

August 8, 2025 | zacks.com

B. Riley Issues Optimistic Estimate for InfuSystem Earnings

August 8, 2025 | marketbeat.com

Roth Capital Predicts InfuSystem's Q4 Earnings (NYSE:INFU)

August 8, 2025 | marketbeat.com

New Strong Buy Stocks for August 8th

August 8, 2025 | zacks.com

InfuSystem Holdings, Inc. (AMEX:INFU) Q2 2025 Earnings Call Transcript

August 6, 2025 | insidermonkey.com

InfuSystem Holdings Reports Mixed Earnings Call Results

August 5, 2025 | tipranks.com

InfuSystem (INFU) Q2 EPS Jumps 300%

August 5, 2025 | fool.com

InfuSystem posts ‘strong’ quarter on back of core biz

August 5, 2025 | hmenews.comH

InfuSystem raises adjusted EBITDA margin outlook to 20%+ as margin expansion continues amid revenue guide revision

August 5, 2025 | msn.com

InfuSystem Holdings, Inc. (INFU) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

InfuSystems Holdings, Inc. (INFU) Tops Q2 Earnings Estimates

August 5, 2025 | zacks.com

InfuSystem Reports Second Quarter 2025 Financial Results

August 5, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMD, BVS, CATX, and INFU Company Descriptions

Bioventus NYSE:BVS

$7.64 +0.56 (+7.91%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.64 0.00 (-0.07%)

As of 08/22/2025 04:10 PM Eastern

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics NYSE:CATX

$3.68 +0.12 (+3.37%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.60 -0.08 (-2.20%)

As of 08/22/2025 08:00 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Cantel Medical NYSE:CMD

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.

InfuSystem NYSE:INFU

$9.57 -0.04 (-0.42%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.57 0.00 (0.00%)

As of 08/22/2025 05:40 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time